VistaGen Therapeutics
VTGN
58 hedge funds and large institutions have $81.8M invested in VistaGen Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 7 closing their positions.
366% more call options, than puts
Call options by funds: $2.68M | Put options by funds: $574K
170% more capital invested
Capital invested by funds: $30.3M → $81.8M (+$51.5M)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
23.02% more ownership
Funds ownership: 53.13% → 76.15% (+23%)
14% more funds holding
Funds holding: 51 → 58 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$12.4M |
| 2 |
O
OrbiMed
New York
|
+$9.14M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.64M |
| 4 |
Renaissance Technologies
New York
|
+$1.14M |
| 5 |
Jane Street
New York
|
+$620K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.43M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$919K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$896K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$219K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$215K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PLU
51
Performa Ltd (US)
Charleston,
South Carolina
| $3.55K | – | – | – |
|
52
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $2K | – | – | – |
|
|
MCM
53
MAI Capital Management
Independence,
Ohio
| $1.87K | – | – | – |
|
|
SS
54
SBI Securities
Tokyo,
Japan
| $1.03K | +$6 | +2 | +0.7% |
|
55
Jones Financial Companies
Des Peres,
Missouri
| $402 | – | – | – |
|
56
BNP Paribas Financial Markets
Paris,
France
| $199 | -$1.26K | -422 | -88% |
|
|
FG
57
Fairman Group
Chesterbrook,
Pennsylvania
| $103 | – | – | – |
|
58
Barclays
London,
United Kingdom
| $4 | – | – | – |
|
|
SFM
59
Sphera Funds Management
Tel Aviv,
Israel
| – | -$896K | -447,939 | Closed |
|
60
Marshall Wace
London,
United Kingdom
| – | -$69.3K | -34,638 | Closed |
|
|
VF
61
Virtu Financial
New York
| – | -$46K | -22,946 | Closed |
|
62
Simplex Trading
Chicago,
Illinois
| – | -$67.3K | -22,536 | Closed |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$15.4K | -7,721 | Closed |
|
64
Raymond James Financial
St Petersburg,
Florida
| – | -$12.8K | -6,410 | Closed |
|
65
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$7K | -3,297 | Closed |
|
VTGN Hedge Fund Activity: Q3 2025 in Review
58 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2025, worth a combined $81.8M — up 170% from $30.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VTGN positions and 7 closed out — a net gain of 7 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $12.4M. The largest seller was JP Morgan Chase, cutting an estimated $1.43M.
- 58 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2025, up from 51 in Q2 2025.
- Funds reported $81.8M of VistaGen Therapeutics stock for Q3 2025, up 170% quarter-over-quarter.
- 14 funds opened new VistaGen Therapeutics positions in Q3 2025 and 7 closed out, a net change of +7 holders.
- The largest VistaGen Therapeutics buyer in Q3 2025 was Janus Henderson Group, an estimated $12.4M added.
- The largest VistaGen Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $1.43M sold.
Based on aggregated 13F filings for Q3 2025.